You have 9 free searches left this month | for more free features.

Bevacizumab

Showing 1 - 25 of 3,098

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation Trial (Onvansertib, FOLFIRI, Bevacizumab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • +2 more
  • (no location specified)
Oct 24, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Colorectal Cancer Trial (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV,

Not yet recruiting
  • Colorectal Cancer
  • HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab
  • HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
  • (no location specified)
Jul 13, 2023

89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

Recruiting
  • Neurofibromatosis 2
  • Bevacizumab Zirconium Zr-89
  • Leiden, Zuid-Holland, Netherlands
    Leiden University Medical Center
Jan 5, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Withdrawn
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Jun 1, 2023

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Adebrelimab, Hepatocellular Carcinoma, Transformation Trial in Xiamen (TACE with adebrelimab and bevacizumab)

Not yet recruiting
  • Adebrelimab
  • +4 more
  • TACE with adebrelimab and bevacizumab
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 25, 2023

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7

Active, not recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Bevacizumab
  • +2 more
  • Los Angeles, California
  • +17 more
Jan 27, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Cancer Center Sun Yat-sen University
Feb 26, 2023

Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8 Trial

Recruiting
  • Resectable Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab
  • +2 more
  • Houston, Texas
  • +1 more
Oct 12, 2022

Colorectal Cancer, Metastatic Colon Cancer Trial (Ompenaclid (RGX-202-01) + FOLFIRI + Bevacizumab, Placebo + FOLFIRI +

Not yet recruiting
  • Colorectal Cancer
  • Metastatic Colon Cancer
  • Ompenaclid (RGX-202-01) + FOLFIRI + Bevacizumab
  • Placebo + FOLFIRI + Bevacizumab
  • (no location specified)
Aug 1, 2023

Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable Trial in Seoul (Atezolizumab plus

Recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Atezolizumab plus bevacizumab, combined EBRT to vascular invasion
  • Atezolizumab plus bevacizumab
  • Seoul, Korea, Republic of
    Asan Medical Center
Aug 7, 2023

Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib alternating with Bevacizumab plus Capecitabine, Bevacizumab plus

Recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib alternating with Bevacizumab plus Capecitabine
  • Bevacizumab plus Capecitabine
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Jan 4, 2023

Hepatocellular Carcinoma Trial in Nanjing, Shanghai (QL1706, Bevacizumab, Oxaliplatin injection)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Nanjing, Jiangsu, China
  • +1 more
Jul 28, 2023

Colorectal Cancer Trial (ME-344, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Apr 20, 2023

Colorectal Cancer Trial (all trans Retinoic Acid, Atezolizumab, Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • all trans Retinoic Acid
  • +2 more
  • (no location specified)
Aug 11, 2023

Colorectal Cancer Metastatic Trial in Guangzhou (Dexamethasone, Anisodamine, Oxaliplatin)

Recruiting
  • Colorectal Cancer Metastatic
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 3, 2023

Hepatocellular Carcinoma Non-resectable Trial in Taoyuan City (Atezolizumab, Bevacizumab, Proton radiotherapy)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Taoyuan City, Taiwan
    Chang Gung Memorial Hospital at Linkou
Nov 17, 2023

Colorectal Cancer, Peritoneal Metastases Trial in Eindhoven, Rotterdam (Irinotecan, FOLFOX regimen, Bevacizumab)

Recruiting
  • Colorectal Cancer
  • Peritoneal Metastases
  • Eindhoven, Netherlands
  • +1 more
Aug 15, 2023

Patterns of Transcatheter Arterial Chemoembolization Combined

Not yet recruiting
  • HCC
  • (no location specified)
Aug 29, 2023

Carcinoma, Ovarian Epithelial Trial in San Fermo Della Battaglia, Padova (Olaparib, Bevacizumab)

Recruiting
  • Carcinoma, Ovarian Epithelial
  • San Fermo Della Battaglia, Como, Italy
  • +1 more
Nov 2, 2023

Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • I-125 Seeds Brachytherapy in PVTT
  • +2 more
  • (no location specified)
Aug 14, 2023

Patients With HHT. Follow up BABH

Completed
  • Hemorrhagic Hereditary Telangiectasia
  • HHT
  • bevacizumab treatment
  • Angers, France
  • +2 more
Sep 8, 2023

Glioblastoma Trial (Tislelizumab and Bevacizumab)

Not yet recruiting
  • Glioblastoma
  • Tislelizumab and Bevacizumab
  • (no location specified)
Apr 12, 2023